The field of cervical cancer prevention is continually evolving. APAOG is part of the Enduring Consensus Cervical Cancer Screening and Management Guidelines effort, a consensus process including 20 clinical, patient representative, and federal partner organizations to provide regular updates to the 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. The Enduring Guidelines process begins with review of new evidence from population-based and other studies and leads to updated guidelines that continually improve clinical management. In March 2024, two papers were published in the Journal of Lower Genital Tract Diseases. The first describes the background, methods, and approach of the effort. The second presents guidelines for the incorporation of p16/Ki67 Dual Stain (Dual Stain) guidelines for evaluating patients with a positive HPV screening test.

The Dual Stain test, commercially available as CINtec® PLUS Cytology, identifies cells in a liquid cytology sample that are often precancerous. Dual Stain is an option for clinicians who choose to use this test; other alternatives remain available. Dual Stain can be used instead of or in addition to liquid cytology (Pap testing) on HPV positive patients to better identify those who require a colposcopy. Resource utilization analyses suggest that compared to cytology, Dual Stain detects precancer earlier and fewer patients need biopsies. For most patients testing HPV positive, colposcopy is recommended for those who also test Dual Stain positive. Follow-up in one (1) year is recommended for most patients testing HPV positive and Dual Stain negative.

Read the full Dual Stain guidelines here:

https://pubmed.ncbi.nlm.nih.gov/38446575/

Read the introductory paper here:

https://pubmed.ncbi.nlm.nih.gov/38446573/